The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

May. 16, 2012
Applicants:

Julie K. Monda, Memphis, TN (US);

Brenda A. Schulman, Memphis, TN (US);

Daniel C. Scott, Memphis, TN (US);

Inventors:

Julie K. Monda, Memphis, TN (US);

Brenda A. Schulman, Memphis, TN (US);

Daniel C. Scott, Memphis, TN (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); C12N 9/99 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); A61K 38/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 14/47 (2006.01); C12N 9/00 (2006.01); G01N 33/573 (2006.01); G01N 33/566 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); C12N 9/93 (2013.01); C12Y 603/02019 (2013.01); G01N 33/566 (2013.01); G01N 33/573 (2013.01); A61K 38/00 (2013.01); C07K 2299/00 (2013.01); G01N 2333/9015 (2013.01); G01N 2440/36 (2013.01); G01N 2500/04 (2013.01);
Abstract

Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).


Find Patent Forward Citations

Loading…